Sorivudine
Systematic (IUPAC) name | |
---|---|
1-β-D-arabinofuranosyl-5-[(E)-2-bromovinyl]pyrimidine-2,4(1H,3H)-dione | |
Clinical data | |
Trade names | Usevir, Brovavir |
Routes of administration | Oral |
Pharmacokinetic data | |
Metabolism | Viral thymidine kinase |
Excretion | Kidney |
Identifiers | |
CAS Number | 77181-69-2 |
ATC code | none |
PubChem | CID 5282192 |
ChemSpider | 4445384 |
UNII | C7VOZ162LV |
KEGG | D01734 |
ChEMBL | CHEMBL375035 |
Synonyms | BV-araU, Bromovinyl araU, 5-Bromovinyl-araU, 5-[(E)-2-bromoethenyl]-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione |
Chemical data | |
Formula | C11H13BrN2O6 |
Molar mass | 349.14 g/mol |
| |
| |
(what is this?) (verify) |
Sorivudine (INN), is a thymine analogue antiviral drug, marketed under trade names such as Usevir (Nippon Shoji, Eisai) and Brovavir (BMS).
Pharmacology
Feature
- First-line treatment of herpes drug acyclovir was (Zovirax, Activir) from VZV strong activity of the virus.
- Superior gastrointestinal absorption, absorption from the gastrointestinal tract after the most degrading without being excreted as urine.
Mechanism of action
- Sorivudine is phosphorylated by thymidine kinase activity in the body and is absorbed into the virus's DNA instead of the correct nucleoside. It is a competitive inhibitor of DNA polymerase, so the viral DNA cannot be replicated and the virus cannot grow.
Microbiology
Sorivudine is active against most species in the herpesvirus family.
- Herpes simplex virus type I (HSV-1)
- Varicella zoster virus (VZV)
- Epstein-Barr virus (EBV)
Interactions
Sorivudine interacts strongly and in some cases lethally with fluorouracil (5-FU), its prodrugs and related substances. This is based on the metabolite bromovinyluracil (BVU), which irreversibly inhibits the enzyme dihydropyrimidine dehydrogenase (DPD) which is necessary for inactivating 5-FU. The closely related drug brivudine has the same interaction.[1]
References
- ↑ "UAW – Aus Fehlern lernen - Potenziell tödlich verlaufende Wechselwirkung zwischen Brivudin (Zostex) und 5-Fluoropyrimidinen" (PDF). Deutsches Ärzteblatt (in German) 103 (27). 7 July 2006.
|
This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.